What's new? Log in Free sign up

Corbus Pharmaceuticals (CRBP)

Company Profile

Company profile

Ticker

CRBP

Exchange

Website

www.corbuspharma.com

CEO

Yuval Cohen

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

SAV Acquisition Corp

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Corbus Pharmaceuticals, Inc. • Corbus International Limited • Corbus Pharmaceuticals Australia Pty Ltd ...

CRBP stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Quarterly report

12 Nov 25

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces Proposed Public Offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Regulation FD Disclosure

Quarterly report

5 Aug 25

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Beneficial ownership report (amended)

Beneficial ownership report

Notice of proposed sale of securities

Notice of proposed sale of securities

Beneficial ownership report (amended)

Corbus Pharmaceuticals Holdings, Inc.

Financial summary

Financial statements Chart CRBP financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	27.65 mm	27.65 mm	27.65 mm	27.65 mm	27.65 mm	27.65 mm
Cash burn (monthly)	(no burn)	(no burn)	8.14 mm	6.33 mm	5.18 mm	4.96 mm
Cash used (since last report)	n/a	n/a	17.81 mm	13.85 mm	11.34 mm	10.85 mm
Cash remaining	n/a	n/a	9.84 mm	13.80 mm	16.31 mm	16.80 mm
Runway (months of cash)	n/a	n/a	1.2	2.2	3.1	3.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CRBP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	105	115	-8.7%
Opened positions	22	34	-35.3%
Closed positions	32	29	+10.3%
Increased positions	34	40	-15.0%
Reduced positions	22	20	+10.0%

13F shares	Current	Prev Q	Change
Total value	126.47 bn	234.63 bn	-46.1%
Total shares	13.38 mm	14.19 mm	-5.7%
Total puts	65.80 k	838.00 k	-92.1%
Total calls	557.00 k	579.20 k	-3.8%
Total put/call ratio	0.1	1.4	-91.8%

Largest owners	Shares	Value	Change
Cormorant Asset Management	2.38 mm	$28.03 bn	0.0%
Cormorant Global Healthcare Master Fund	1.48 mm	$0.00	0.0%
Orbimed Advisors	1.17 mm	$13.83 bn	+28.5%
Octagon Capital Advisors	1.12 mm	$13.16 bn	0.0%
BlackRock	873.37 k	$10.31 bn	+8.8%
Vanguard	659.20 k	$7.78 bn	+2.1%
Adage Capital Partners GP, L.L.C.	528.94 k	$6.24 bn	0.0%
Adage Capital Management	528.94 k	$8.76 mm	0.0%
Integrated Core Strategies	419.71 k	$14.69 mm	0.0%
Millennium Management	386.65 k	$4.56 bn	+276.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	228.60 k	-366.98 k	-61.6%
Tang Capital Management	242.65 k	-357.35 k	-59.6%
Millennium Management	386.65 k	+283.90 k	+276.3%
Orbimed Advisors	1.17 mm	+259.74 k	+28.5%
Armistice Capital	236.00 k	+236.00 k	NEW
Ikarian Capital	51.43 k	-233.28 k	-81.9%
Assenagon Asset Management	0.00	-221.18 k	EXIT
Altium Capital Management	385.00 k	+190.00 k	+97.4%
T. Rowe Price	164.74 k	-160.93 k	-49.4%
Ghost Tree Capital	0.00	-160.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRBP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Oct 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	17.14	8,973	153.80 k	138,187
27 Oct 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Option exercise	Acquire M	No	No	4.26	8,973	38.22 k	147,160
27 Oct 25	Cohen Yuval	Stock options Common Stock	Option exercise	Dispose M	No	No	4.26	8,973	38.22 k	22,106
24 Oct 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	17.01	18,660	317.41 k	138,187
24 Oct 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Option exercise	Acquire M	No	No	4.26	18,660	79.49 k	156,847
24 Oct 25	Cohen Yuval	Stock options Common Stock	Option exercise	Dispose M	No	No	4.26	18,660	79.49 k	31,079
24 Oct 25	Sean F. Moran	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	17.02	12,981	220.94 k	73,313
24 Oct 25	Sean F. Moran	Common Stock, par value $0.0001 per share	Option exercise	Acquire M	No	No	4.26	12,981	55.30 k	86,294
24 Oct 25	Sean F. Moran	Stock options Common Stock	Option exercise	Dispose M	No	No	4.26	12,981	55.30 k	10,386
20 Oct 25	Anne Altmeyer	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	20.5	1,060	21.73 k	6,191

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $53

RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $55 to $53.

Corbus Pharmaceuticals Q3 EPS $(1.90) Misses $(1.72) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.72) by 10.72 percent. This is a 65.22 percent decrease over losses of $(1.15) per

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Roku, SPS Commerce, Newell Brands And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Press releases

From Benzinga Pro

Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced the pricing of an underwritten public

Corbus Pharmaceuticals Announces Proposed Public Offering

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced that it plans to offer and sell shares

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.